Glumetinib for lung cancer with MET changes
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests how well glumetinib works for non-small cell lung cancer (NSCLC) that has specific “MET” gene changes. It also checks safety and side effects, especially in people who can’t have surgery or have already had other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an adult (18 or older, or the age of majority where you live) and sign consent
- Have confirmed non-small cell lung cancer (NSCLC), including people with a specific subtype (PSC)
- Have stage IIIb/IIIc not suitable for curative surgery or chemo-radiation, or stage IV cancer
- Your tumor must show a MET change (examples: MET exon 14 skipping, MET amplification, or MET over-expression) checked by local and/or central testing
- Have enough body strength to do daily activities (ECOG performance status 0–1) and adequate blood, liver, kidney levels
- If you’re in the Phase II part, you must have had 1–2 prior treatment “lines” for advanced cancer (or you can’t/choose not to have chemotherapy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of two medicines for people with advanced non-small cell lung cancer that has a specific marker called MET overexpression. The trial hopes to see if adding the new drug (glumetinib) to standard chemotherapy works better than chemotherapy alone.
This trial tests a targeted drug for advanced non-small cell lung cancer that has a specific genetic change called MET exon 14 skipping. It aims to see if the drug can shrink tumors or slow the cancer's growth, and may help people who have or haven't had prior treatment.
This Phase 2 study tests ABN401 to see how well it works and how safe it is for people with advanced non-small cell lung cancer (NSCLC) that has certain c-MET (a protein) changes. It may help some tumors that have not responded well to prior treatment, especially certain EGFR-related cases.
This trial tests a new drug called SKB571 for people with advanced lung cancer that has a specific change in the MET gene. The goal is to see if the drug can shrink tumors or stop them from growing.
This trial tests a combination of two drugs, glumetinib and nab-docetaxel, in people with advanced stomach cancer or other solid tumors that have a specific change in the MET gene. The goal is to see if this combination is safe and works better than current treatments.
This Phase 2 trial tests combinations of targeted medicines to treat advanced non-small cell lung cancer (NSCLC) that has changes in both EGFR and MET genes. It is for people whose cancer continued to grow even after treatment with osimertinib, the most recent therapy.
Hear when a new C-Met Exon 14 Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.